Grace Therapeutics Inc. (GRCE)
NASDAQ: GRCEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
GRCE stock chart
Technical analysisKey statistics
All statistics- Market cap
- $35.97M
- EPS (TTM)
- -$1.16
- Dividend yield
- None
- 52-week range
- 1.64 – 5.18
- Day range
- 1.68 – 1.82
- Volume / Avg
- 153.91K / 119.27K
- Beta
- —
- Shares outstanding
- 21.04M
52-week range
GRCE stock today
Grace Therapeutics (GRCE) closed at $1.71 on Nov 20, down 0.58% (-$0.01), versus the S&P 500's 3.70% decline. Shares are 67.0% below their 52-week high of $5.18, set on Apr 2, 2026 and 4.3% above the 52-week low of $1.64, near the bottom of the past year's range. GRCE is down 50.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 46.4%.
Grace Therapeutics has posted a net loss over the last twelve months (EPS of -$1.16), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Grace Therapeutics
Company profileGrace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an injectable formulation developed to treat aneurysmal subarachnoid hemorrhage.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Prashant Kohli
- Headquarters
- Princeton, NJ
- Employees
- 5
- Website
- gracetx.com
Financial highlights
Full financialsGrace Therapeutics reported a net loss of $7.8 million, compared with a loss of $9.6 million a year earlier. Diluted earnings per share came in at -$0.47.
| Fiscal year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | $100.00M |
| Growth | — | — | — | — | +50920.41% |
| Net income | $-7.79M | $-9.57M | $-12.85M | $-42.43M | $-9.82M |
| EPS (diluted) | $-0.47 | $-0.79 | $-1.35 | $-5.71 | $-0.27 |
Analyst forecast
ForecastConsensus (2 analysts)
none
Avg. price target
$5.87+243.27%
- Strong buy 0
- Buy 2
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-0.11 vs —
GRCE news
All GRCE news- Grace Therapeutics Q2 Loss Widens Without Prior-Year Warrant Gain; Advances GTx-104 PlansNasdaqGRCE, LEN.B
- Grace Therapeutics, Inc. Reports Financial Results for the Three Months Ended September 30, 2026 and Provides GTx-104 UpdateNasdaq
- Grace Therapeutics Announces Second Quarter 2027 Financial Results, Provides Business UpdateGlobeNewswire
- Grace Therapeutics Announces Participation in Upcoming Industry and Investor Events in November 2026GlobeNewswire
Grace Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PLRXPliant Therapeutics Inc. | 0.5951 | -4.02% | $36.89M | vs GRCE |
| SDEVStablecoin Development Corporation | 0.50 | -10.30% | $36.90M | vs GRCE |
| CNTBConnect Biopharma Holdings Limited | 0.59 | -6.08% | $38.05M | vs GRCE |
| CUECue Biopharma Inc. | 4.15 | -7.78% | $34.69M | vs GRCE |
| DWTXDogwood Therapeutics Inc. | 1.04 | -2.36% | $39.57M | vs GRCE |
| VERUVeru Inc. | 1.94 | -8.06% | $33.08M | vs GRCE |
| ATNMActinium Pharmaceuticals Inc. (Delaware) | 1.05 | -1.87% | $33.01M | vs GRCE |
| HYFTMindWalk Holdings Corp. | 0.6844 | -14.27% | $32.56M | vs GRCE |
Indexes, lists and sector
Grace Therapeutics stock FAQ
What is Grace Therapeutics's stock price today?
GRCE last traded at $1.71 as of Nov 20, 4:00 PM EST, down 0.58% on the day. Prices are delayed at least 15 minutes.
Does Grace Therapeutics pay a dividend?
No. Grace Therapeutics does not currently pay a regular cash dividend.
Who is Grace Therapeutics's CEO?
Mr. Prashant Kohli is the chief executive officer of Grace Therapeutics Inc., which has about 5 employees.
Has GRCE ever split its stock?
Yes. The most recent GRCE stock split was a 1-for-6 split on Jul 10, 2023, one of 3 splits on record.
What is the GRCE 52-week high?
The 52-week high for GRCE is $5.18 and the 52-week low is $1.64. The stock is currently 67.0% below its high.